Health

Allergan's acute migraine treatment wins U.S. FDA approval


A sign marks Allergan’s offices in Medford, Massachusetts, U.S., July 31, 2017. REUTERS/Brian Snyder

(Reuters) – The U.S. Food and Drug Administration said on Monday it had approved Allergan Plc’s drug for treating acute migraine in adults.

The drug, Ubrelvy, is the first oral version of a new class of drugs called CGRP inhibitors to win the FDA’s approval for treating the neurological disease. (bit.ly/2QeY1b7)

The new class of drugs acts by interfering with CGRP, a protein involved in causing severe headaches.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli



READ SOURCE

Leave a Reply

This website uses cookies. By continuing to use this site, you accept our use of cookies.